ICU MEDICAL, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 96.38 USD | +0.64% |
|
-0.74% | -3.37% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company has a low valuation given the cash flows generated by its activity.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company has insufficient levels of profitability.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -3.37% | 2.35B | C+ | ||
| -2.73% | 186B | C+ | ||
| -2.20% | 107B | C | ||
| -4.08% | 67.57B | A | ||
| +5.99% | 50.7B | B- | ||
| +15.32% | 47.2B | B- | ||
| -0.45% | 39.72B | B+ | ||
| +6.60% | 27.48B | A- | ||
| -1.11% | 25.65B | B | ||
| -0.76% | 24.82B | B |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ICUI Stock
- Ratings ICU Medical, Inc.
